StemCell Therapy

Palatin Technologies, Inc. (PTN) is near the top in its industry group according to InvestorsObserver. PTN gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Palatin Technologies, Inc. gets a 52 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Palatin Technologies, Inc. (PTN) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Palatin Technologies, Inc. (PTN) stock is down -7.31% while the S&P 500 has risen 0.09% as of 1:53 PM on Friday, Jan 10. PTN has fallen -$0.05 from the previous closing price of $0.74 on volume of 1,958,045 shares. Over the past year the S&P 500 is up 26.22% while PTN has fallen -8.00%. PTN earned $0.14 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.98.

To screen for more stocks like PTN click here.

Read more:
Is Palatin Technologies, Inc. (PTN) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

This entry was posted on January 10, 2020 at 9:51 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |